Novel approach for a PTX/VEGF dual drug delivery system in cardiovascular applications—an innovative bulk and surface drug immobilization
- 12 March 2018
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 8 (3) , 719-728
Abstract
The successive incorporation of several drugs into the polymeric bulk of implants mostly results in loss of considerable quantity of one drug, and/or the loss in quality of the coating and also in changes of drug release time points. A dual drug delivery system (DDDS) based on poly-l-lactide (PLLA) copolymers combining the effective inhibition of smooth muscle cell proliferation while simultaneously promoting re-endothelialization was successfully developed. To overcome possible antagonistic drug interactions and the limitation of the polymeric bulk material as release system for dual drugs, a novel concept which combines the bulk and surface drug immobilization for a DDDS was investigated. The advantage of this DDDS is that the bulk incorporation of fluorescein diacetate (FDAc) (model drug for paclitaxel (PTX)) via spray coating enhanced the subsequent cleavable surface coupling of vascular endothelial growth factor (VEGF) via the crosslinker bissulfosuccinimidyl suberate (BS3). In the presence of the embedded FDAc, the VEGF loading and release are about twice times higher than in absence. Furthermore, the DDDS combines the diffusion drug delivery (FDAc or PTX) and the chemical controlled drug release, VEGF via hydrolysable ester bonds, without loss in quantity and quality of the drug release curves. Additionally, the performed in vitro biocompatibility study showed the bimodal influences of PTX and VEGF on human endothelial EA.hy926 cells. In conclusion, it was possible to show the feasibility to develop a novel DDDS which has a high potential for the medical application due to the possible easy and short modification of a polymer-based PTX delivery system.Keywords
This publication has 33 references indexed in Scilit:
- Drug-Eluting or Bare-Metal Stents for Coronary Artery DiseaseNew England Journal of Medicine, 2016
- Nitric oxide producing coating mimicking endothelium function for multifunctional vascular stentsBiomaterials, 2015
- Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular DiseaseGlobal Heart, 2015
- Coronary drug‐eluting stents: From design optimization to newer strategiesJournal of Biomedical Materials Research Part A, 2013
- Coronary stents: historical development, current status and future directionsBritish Medical Bulletin, 2013
- The use of drug-eluting stents in acute myocardial infarction – is the battle coming to an end? From despair to acceptanceAdvances in Interventional Cardiology, 2013
- In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin–collagen multilayerBiomaterials, 2010
- Molecular Basis of Restenosis and Novel Issues of Drug-Eluting StentsCirculation Journal, 2009
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994